References
- Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008;15:661–6
- Stefanick ML. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med 2005;118:64–73
- Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509–22
- Position Statement. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888–902
- Padwick ML, Endacott J, Matson C, Whitehead MI. Absorption and metabolism of oral progesterone when administered twice daily. Fertil Contracept 1986;46:402–7
- Hayashi T, Ito I, Kano H, Endo H, Iguchi A. Estriol (E3) replacement improves endothelial function and bone mineral density in very elderly women. J Gerontol A Biol Sci Med Sci 2000;55:B183–90
- Takahashi K, Okada M, Ozaki T, et al. Safety and efficacy of oestriol for symptoms of natural or surgically induced menopause. Hum Reprod 2000;15:1028–36
- Nakayama H, Yano T, Sagara Y, et al. Estriol add-back therapy in the long-acting gonadotropin releasing hormonal agonist treatment of uterine leiomyomata. Gynecol Endocrinol 1999;13:382–9
- López-Belmonte J, Nieto C, Estevez J, Delgado JL, del Prado JM. Comparative uterine effects on ovariectomized rats after repeated treatment with different vaginal estrogen formulations. Maturitas 2012;72:353–8
- Hustin J. Estrogen treatment of postmenopausal vaginal atropy – a cytological assessment. Maturitas 1979,1:207–13
- Dixon WJ, Massey FJ. Introduction to Statistical Analysis, 4th edn. New York: McGraw-Hill, 1983.
- O'Brien RG, Muller KE. Applied Analysis of Variance in Behavioral Science. New York: Marcel Dekker, 1983:297–344
- Stolley P, Strom B. Sample size calculations for clinical pharmacology studies. Clin Pharmacol Ther 1986;39:489–90
- Zar J. Biostatistical Analysis, 2nd edn. Nerw Jersey: Prentice-Hall, 1984.
- Barentsen R, van de Weijer PHM, Schram JHN. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol 1997;71:73–80
- Cano A, Estévez J, Usandizaga R. The therapeutic effect of a new ultra low concentration estriol formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal clinical trial. Menopause 2012;19:1130–9
- Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 2004;22:4261–71
- Hickey M, Saunders C, Partridge A, Santoro N, Joffe H, Stearns V. Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol 2008;19:1669–80